<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765919</url>
  </required_header>
  <id_info>
    <org_study_id>1356</org_study_id>
    <nct_id>NCT02765919</nct_id>
  </id_info>
  <brief_title>A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix</brief_title>
  <official_title>Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two diffrent brachytherapy treatment option in
      locally advanced carcinoma of uterine cervix. Brachytherapy of two fractions of 9 Gy is
      effective in locoregional control and more convenient in terms of cost and time than 7 Gy
      brachytherapy of 3 fractions in management of locally advanced carcinoma of cervix.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer is the second most common cancer among women worldwide and is the commonest
      form of gynecolgic malignancy in Bangladesh.Radiotherapy in the form of external beam
      radiotherapy combined with intracavitary Brachytherapy is the accepted definitive mode of
      treatment.Limiting the number of high dose rate(HDR) Brachytherapy has the potential benefit
      of improving patient compliance and reducing treatment cost and duration.The aim of this
      study is to compare the treatment outcome and acute complications following treatment with 9
      Gray (Gy) in two fractions of brachytherapy with standard EBRT in locally advanced carcinoma
      of cervix.

      EBRT will be delivered by a cobalt 60 teletherapy unit to a prescribed dose of 50 Gy in 25
      fractions of 2 Gy per fraction and 5 days a week over a period of 5 weeks concurrent with
      inj. Cisplatin 40 mg/meter square weekly for 5 weeks.The patients will be then randomised
      into two arms of HDR brachytherapy,either 9Gy in 2 fractions or 7 Gy in 3 fractions.All
      patients will be followed up as per guideline for 6 months.The treatment related toxicity
      will be measured by Common Toxicity Criteria(Common terminology criteria for adverse events
      v.3.0).

      All the relevant collected data will be compiled on a master chart and then statistical
      analysis of the results will be obtained by using SPSS 17.The data will be analysed using Chi
      square test and T test.Significant value will be decided at a level of 0.05 in two tailed
      tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of tumor size in cervix</measure>
    <time_frame>Six month</time_frame>
    <description>Comparison of pre treatment tumor size with post treatment tumor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of Cervix</condition>
  <arm_group>
    <arm_group_label>Radiation HDR Brachytherapy 9 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation HDR Brachytherapy 7 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR Brachytherapy of 9 Gy in 2 fractions</intervention_name>
    <description>Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix</description>
    <arm_group_label>Radiation HDR Brachytherapy 9 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR Brachytherapy of 7 Gy in 3 fractions</intervention_name>
    <description>Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix</description>
    <arm_group_label>Radiation HDR Brachytherapy 7 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced carcinoma cervix (stage 2b - 4a)

          -  Histopathology squamous cell carcinoma

        Exclusion Criteria:

          -  Previous history of malignancy

          -  Previously treated with radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Abdul Bari, MBBS,MPhil</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor,dept.of Oncology,BSMMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Israt Jahan, MBBS</last_name>
    <phone>+8801726195389</phone>
    <email>isratneeturt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammad Abdul Bari, MBBS,MPhil</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BSM Medical University</name>
      <address>
        <city>Dhaka</city>
        <zip>1200</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israt Jahan, MBBS</last_name>
      <phone>01726195389</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <link>
    <url>http://www.bsmmu.edu.bd</url>
  </link>
  <results_reference>
    <citation>Patel FD, Rai B, Mallick I, Sharma SC. High-dose-rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):125-30.</citation>
    <PMID>15850912</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Israt Jahan</investigator_full_name>
    <investigator_title>Resident,Dept. of Oncology,BSMMU</investigator_title>
  </responsible_party>
  <keyword>Carcinoma cervix</keyword>
  <keyword>RCT(randomised controlled trial)</keyword>
  <keyword>9 Gray</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

